Purpose: T 2 MRI oximetry can noninvasively determine oxygen saturation (Y) but requires empirical MR calibration models to convert the measured blood transverse relaxation (T 2b ) into Y. The accuracy of existing T 2b models in the presence of blood disorders such as sickle cell disease (SCD) remains unknown. Methods: A Carr Purcell Meiboom Gill T 2 preparation sequence was used to make 83 whole blood measurements from 11 subjects with SCD to derive an ex vivo sickle hemoglobin (HbS) T 2b model. Forearm venous blood gas, sagittal sinus T 2 (T 2 Relaxation Under Spin Tagging) and total brain blood flow (phase contrast MRI) were measured in 37 healthy controls and 33 SCD subjects (age 24.6 6 10.2 years). Cerebral oxygen saturation, extraction fraction, and metabolic rate estimates were calculated using three separate T 2b models. Cerebral and forearm oxygen extraction fraction were compared. Results: Ex vivo, SCD blood had greater saturation dependent relaxivity than control blood, with a weak dependence on HbS and no dependence on hematocrit. In vivo, the HbS T 2b model predicted Y v values with lowest coefficient of variation (compared with existing T 2b models) and the strongest correlation with peripheral venous oximetry (r 2 ¼ .29). The HbS T 2b model predicted systematically higher Y v measurements in SCD patients (73 6 5 and 61 6 6; P < 0.0001) which was mirrored by peripheral venous measurements (75 6 20 and 45 6 20; P < 0.0001). Conclusion: Cerebral and peripheral oxygen extraction are decreased in SCD patients, suggesting either blood flow is increased beyond metabolic demands or the presence of physiological arterial-venous shunting. Magn Reson Med 80:294-303,
INTRODUCTION
Cerebral MRI oximetry is a promising technology because it offers a noninvasive metric of venous oxygen saturation and oxygen extraction fraction (OEF) (1) . When paired with a MRI-based cerebral blood flow (CBF) technique such as arterial spin labeling (2) or phase contrast (3), MRI oximetry allows for calculation of cerebral metabolic rate of oxygen (CMRO 2 ) quickly and easily within a single MRI examination (4) .
Several techniques for MRI oximetry exist, all of which use the fact that hemoglobin undergoes a change in magnetic susceptibility when transitioning from the oxyghemoglobin to deoxyhemoglobin configuration (5) . Of these, T 2 relaxation under spin tagging (TRUST)(1) is the most widely reported MRI oximetry technique because it is easily performed, reproducible, rapid and well tolerated (6) . TRUST uses arterial spin labeling to magnetically tag and isolate blood in the sagittal sinus and a Carr Purcell Meiboom Gill (CPMG) (7) T 2 preparation pulse train to apply T 2 weighting to blood, allowing for the determination of the blood transverse relaxation (T 2b ). Predetermined MR signal models relating T 2b and oxygen saturation (Y) are then used to convert the measured T 2b into venous oxygen saturation (Y v ) in vivo. Due to the ease and efficacy of TRUST MRI, there are several recent reports of Y v , OEF, and CMRO 2 in several pathologic and physiologic states and conditions, including vascular aging, drug addiction, multiple sclerosis, and sickle cell disease (8) (9) (10) (11) .
Although TRUST has excellent intersubject, interscan, and intersession reproducibility (6) , the accuracy of MR oximetry in pathologic blood conditions, such as sickle cell disease, remains an open question. The most commonly used T 2b model for oximetry calibration was derived from bovine blood (which has smaller cells that do not exhibit red cell aggregation) and is defined over a range of hematocrit not applicable for anemic patients (12, 13) .
To strengthen the reliability of TRUST and T 2 based MRI oximetry in patients with sickle cell disease, this work sought to determine the impact of sickle hemoglobin (HbS) on ex vivo T 2b model calibrations and derived Y v , OEF, and CMRO 2 estimates in healthy controls and patients with sickle cell disease.
METHODS
All studies were performed at Children's Hospital Los Angeles and approved by the Committee on Clinical Investigation (CCI# 11-00083). Informed consent or assent was obtained from all study participants. The study was performed in two separate segments: ex vivo T 2b signal model determination and in vivo brain imaging. Participants were separated into two study populations: healthy control subjects (CTL) and subjects with sickle cell disease (SCD). We restricted the population to adolescents and young adults without previous overt strokes or known cerebrovascular disease. Other exclusion criteria were the following: (i) pregnancy; (ii) occurrence of acute chest or pain crisis hospitalization within 1 month; and (iii) additional conditions such as epilepsy or traumatic brain injury.
TRUST Imaging
All imaging was performed on a Philips Achieva 3T MR system with an eight-channel, receive only head coil.
The in vivo, TRUST pulse sequence used in this study is thoroughly explained in prior publications (12, 13) . Briefly, a transverse, single slice TRUST sequence was used to measure T 2b in the sagittal sinus. The TRUST sequence consisted of a pulsed arterial spin labeling tag, a CPMG T 2 preparation module, 1022-ms delay and an echo planar readout (Fig. 1) . Pairwise subtraction of images with and without tagging were used to render a difference image that isolated venous blood (Fig. 2) . The interecho spacing (tau) of the CPMG module was 10ms. Phase cycled, MLEV16 composite pulses were used to limit off resonance effects (90x 180y 90x ). The number of inversion pulses were varied across four image acquisitions (0, 4, 8, 16 pulses) to acquire difference images with effective echo times of 0 ms, 40 ms, 80 ms, and 160 ms. A 1022-ms delay after T 2 preparation was used to allow tagged blood to reach the sagittal sinus where images were acquired with a single-shot echo planar readout, TR/TE, 1978/3.77 ms.
The difference signal in the sagittal sinus was averaged and the four measured eTE were fit to the monoexponential decay equation:
where DSignal 0 is constant across echo times and T 1b is the blood longitudinal relaxation. A fixed T 1b was used in patients with SCD (14) and hematocrit corrected T 1b was used in the CTL subjects (14, 15) .
Blood Experiments
The TRUST sequence was modified for the ex vivo blood measurements to reduce the field of view and disable the ASL tagging because there was no blood flow. Additionally, a three-shot acquisition was used to reduce boundary susceptibility artifacts. A head-to-head comparison with and without ASL and EPI modifications demonstrated no statistical difference in T 2 estimation (-1.2% 6 5.1%). The remaining CPMG T 2 preparation sequence parameters included a repetition time of 1978 ms, 110 cm FOV, 5-mm slice thickness and in plane resolution of 1.7 mm. These modifications did not alter the fundamental measured T 2b (13) .
Approximately 30 mL of blood was acquired from the antecubital vein into heparinized tubes. A small aliquot was immediately (<10 min) used for determination of peripheral venous oxygen saturation (Alere Inc., EPOC Blood Analysis System, Walthan, MA). Complete blood count and hemoglobin electrophoresis was also performed. Remaining blood was placed at 4 C until analysis. All studies were performed within 12 h of phlebotomy.
The remaining blood was warmed and reoxygenated by ambient exposure to room air during ex vivo experimentation. Oxygen saturation, hemoglobin, methemoglobin, and carboxyhemolgobin were measured using a bench top CO-oximeter (Radiometer, OSM3, Copenhagen, Denmark). The blood was intentionally left at the native hematocrit level, as to disturb the blood samples as little as possible, increasing reliability of T 2b estimates but lowering the measurable hematocrit range. Representative TRUST images showing the anatomical, control images the first and third effective echo time and the resulting difference image upon subtraction of the control and labeled TRUST images. Yellow arrows correspond to the isolated blood signal in the sagittal sinus of the difference images. C: Mono-exponential fitting of all four difference images is then performed to estimate T 2b that is then converted to a blood oxygenation value using empirically derived blood calibrations. D: Phase contrast, phase-based velocity image of the four major cerebral feeding vessels of the neck demonstrate how velocity and global CBF can be quantified.
A previously described, custom blood phantom chamber was used to image the blood samples within the MRI scanner (13) . The blood phantom chamber was sealed to the atmosphere and temperature controlled to 37 C. All blood images were acquired in the sagittal orientation. Once the blood reached 37 C, it was gently agitated by aspiration with a syringe system and then sealed from the atmosphere. The blood oxygen saturation was then measured on the table top CO-oximeter and MR imaging was initiated. Next, a series of three TRUST images were performed: first t ¼ 10 ms, next t ¼ 20 ms and then another t ¼ 10 ms. The blood sample was gently agitated before each image acquisition to reduce blood sedimentation and aggregation (13) . Temperature and blood oxygen saturation were measured following each imaging series. Blood was then removed from the imaging phantom and placed inside a temperature-controlled gas chamber and deoxygenated using 37 C, humidified gas and a membrane oxygenator (Living System Instrumentation, Burlington, VT). The gas mixture used for deoxygenation was 95% N 2 and 5% CO 2 to maintain a physiologic pH. The blood was deoxygenated by 10-30% and then was placed back into the blood phantom chamber for imaging. The blood was again gently agitated, temperature and blood oxygenation were measured, and the imaging series was repeated. TRUST imaging and deoxygenation were repeated until the blood reached an oxygen saturation of approximately 30%. The blood was then safely discarded.
Linear regression was used to determine and correct for reoxygenation and aggregation mediated T 2 drift (13) .
Following completion of the ex vivo T 2b measurements, T 2b was derived by applying monoexponential fitting to the blood pool signal and the values were fit to a bilinear relationship of hematocrit (Hct) and oxygen saturation (Y) as follows:
where A 1 , A 2, A 3 , and A 4 are empirically determined coefficients (13) .
In Vivo Imaging
Phase Contrast
In addition to TRUST, whole brain cerebral blood flow was measured using phase contrast MRI (3). Cerebral blood flow data has been previously reported in these patients (13, 16) . In short, a single, two dimensional phase contrast slice was positioned approximately 1-5 cm superior to the carotid bifurcation and optimally orthogonal to both carotid and vertebral arteries (Fig. 2) . Image parameters included 260 Â 260 mm FOV, TE ¼ 7.5 ms, 5-mm slice thickness, 150 cm/s velocity encoding gradient (VENC), 10 signal averages. Vessel boundaries were semi-automatically segmented from the complex difference images using Canny edge detection and mapped to the phase difference image for flow calculation. The coefficient of variation of these measurements was 4.6% 6 3.5% over a 30-min interval (16).
Phlebotomy for complete blood count, venous blood gas, and hemoglobin electrophoresis were performed on all subjects. Fingertip pulse oximetry was measured continuously throughout the MRI examination.
Calculated Parameters
In vivo TRUST Y v values from SCD patients were subsequently calculated using three different T 2b models, (i) the original bovine calibration (12), (ii) the calibration previously reported using the blood of healthy subjects (13) , and (iii) the newly derived HbS specific, SCD calibration. Linear regressions of oxygen saturation, oxygen extraction, and cerebral metabolic rate of oxygen versus oxygen content were performed to examine the influence of T 2b model on physiologic oxygenation predictions. Regression coefficients were compared using a z-score test of equality (17) .
Several physiological parameters were derived. Cerebral metabolic rate of oxygen (CMRO 2 ) was defined as:
where C a O 2 and C v O 2 are the arterial and venous oxygen contents, respectively:
where pO 2 is the vessel specific partial pressure of oxygen and Y a is the arterial oxygen saturation. Pulse oximetry and phlebotomy were used to obtain Y a and hemoglobin, respectively, for oxygen content quantification. Because arterial and venous blood gasses were not obtained, the partial pressure of oxygen was assumed to be 100 torr in the systemic circulation and 40 torr in the venous circulation. Therefore, CMRO 2 can be rewritten as:
where OEF is the oxygen extraction fraction defined as:
RESULTS
The blood of 11 patients with SCD (5 HbSS, 2 HbSS receiving transfusion therapy, 1 HbSC, 2 HbSb þ , 1 HbSb 0 ) was separately studied for a total of 83 HbS T 2b measurements over a range of physiologically relevant oxygen saturation values (18-99%) and hematocrit levels (24-40%). The white blood cell count was 10.8 6 7.3 cells/dL, reticulocyte count 7.4 6 4.9%, hemoglobin F% 6.3 6 9.9% and HbS% 66.4 6 22.1% across the blood samples from subjects with SCD.
Neither the bovine nor the HbA T 2b model from Equation [2] , adequately fit the observed T 2b relationship for sickle cell blood (Fig. 3) . Hematocrit had no influence on the measured T 2b for both fully saturated (>95% saturation) (Fig. 3) and desaturated HbS blood, (r 2 ¼ 0.00090; P ¼ 0.79). Although the inverse of T 2b was highly dependent on (1-Y) 2 , the slope of this relationship was steeper than that observed with the previously derived HbA T 2b model (Fig. 3) . Given these findings, we defined the following data driven, hematocrit independent, linear HbS T 2b model:
where A was 70.0 and B was 5.75 when a tau ¼ 10 ms was used and 93.1 and 7.16 when tau ¼ 20 ms. This relationship demonstrated an r 2 ¼ 0.98, P < 0.0001. The residual of this relationship was weakly dependent on HbS percentage r 2 ¼ 0.04, P ¼ 0.03, but was not included in the model because HbS% is not routinely known when patients with SCD undergo brain MRI.
Additionally, a total of 18 measurements where made using the blood of two subjects with sickle cell trait, HbS % 29.9 6 3.3. The T 2b measurements were statistically identical to the HbA T 2b model (Fig. 3) .
The 3D relationships between T 2b , hematocrit, and oxygen saturation produced by each T 2b model can be seen in Figure 4 . The differences in T 2b model formulation translated into model specific predictions of Y v , OEF, and CMRO 2 when using TRUST MRI in vivo.
In Vivo Brain Imaging
Brain MRI examinations were performed on 70 subjects to determine Y v , OEF, and CMRO 2 using TRUST MRI. Additional demographic information can be found in Table 1 . The most widely used T 2b model was derived using bovine blood over hematocrit values of 35-55% and is highly nonlinear at low hematocrit. Middle: The HbA model (13) was calibrated across hematocrit values of 10-55% using blood of healthy subjects and demonstrates a bilinear relationship between 1/T 2b , hematocrit, and (1-Y) 2 . The gray circles represent individual measurements. Right: The ex vivo T 2b model derived in this work is fairly distinct from both aforementioned T 2b models, demonstrating no hematocrit dependence. The red asterisks denote the individual ex vivo measurements used to derive the T 2b model fits.
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The average cerebral flow and oxygenation parameters measured by PC and TRUST MRI varied between populations and T 2b models (Table 1 ). Using the bovine T 2b model, Y v was lower and OEF trended higher in the SCD patients compared with controls. In contrast, the HbA T 2b model yielded systematically higher Y v values for SCD patients and lower Y v values for controls. The difference in absolute oxygenation percentage using the bovine calibration compared with the HbA was -3 6 1% in CTL (P < 0.0001) and 4 6 4% in SCD (P < 0.0001). The newly derived HbS T 2b model demonstrated even larger differences for SCD patients, with the absolute differences in Y v increasing to 13 6 6.4% in SCD (P < 0.0001). Although the coefficients of variation were similar in controls across T 2b models (bovine 9.2% and HbA 9.8%), the HbS demonstrated the lowest coefficient of variation in SCD subjects (bovine 13.3%; HbA 9.4%; HbS 6.8%).
Insight into these model discrepancies can be gained from regression analysis with oxygen content. According to the bovine model, increasing anemia was associated with progressively lower Y v , as well as increased OEF and CMRO 2 (Fig. 5) . However, the HbA and HbS calibrations exhibited completely different physiologic predictions. The HbA T 2b model demonstrated no relationship between Y v and oxygen content. In contrast, the HbS T 2b model predicted that Y v varies inversely with oxygen content. The linear coefficients (mean 6 standard error) for the bovine (slope ¼ 1.2 6 0.2; intercept ¼ 42.8 6 3.8; P < 0.0001; r 2 ¼ 0.29), HbA (slope ¼ -0.08 6 0.2; intercept ¼ 64.8 6 3.7; P ¼ 0.7; r 2 ¼ .002), and HbS (slope ¼ -1.3 6 0.2; intercept ¼ 87.5 6 3.5; P < 0.0001; r 2 ¼ .30) T 2b models were all significantly different from one another (P < 0.01).
The systematic Y v differences across T 2b models also gave rise to conflicting relationships between OEF, CMRO 2 and oxygen content (Fig. 6 ). OEF and CMRO 2 were negatively correlated with oxygen content in the bovine model (Fig. 6 , left panels), were independent of oxygen content in the HbA model (Fig. 6 , center panels) 5 . TRUST oximetry derived, in vivo venous oxygen saturation predictions in healthy subjects (gray circles) and subjects with sickle cell disease (red diamonds) with respect to oxygen content using three separate T 2b models. Each model demonstrates a unique physiological relationship between oxygen content and cerebral venous oxygen saturation. The bovine T 2b (left) predicts an increasing oxygen venous saturations with respect to oxygen content (r 2 ¼ 0.21; P < 0.0001) whereas the newly derived HbS model (right) predicts a diametrical opposite relationship (r 2 ¼ 0.29; P < 0.0001). The HbS model statistically outperformed the other models in SCD patients, producing the lowest coefficient of variation (bovine 13.3%; HbA 9.4%; HbS 6.8%).
and were positively correlated with oxygen content in the HbS model (Fig. 6, right panels) .
To place the different cerebral oximetry predictions into physiological context, we also measured antecubital vein Y v and OEF using cooximetry of venous blood samples. The peripheral Y v measurements were higher in the SCD (74.9 6 20.5%) compared with the CTL group (45.0 6 19.9%) (Fig. 7) , most similar to cerebral Y v predictions using the HbS T 2b model. Peripheral OEF estimates had the strongest correlation with cerebral OEF estimates made using the HbS model (P < 0.0001; r 2 ¼ 0.30), were weakly correlated with the HbA model (P ¼ 0.009; r 2 ¼ 0.14) and were uncorrelated when the bovine model was used (P ¼ 0.7; r 2 ¼ 0.003). Upon
Derived estimates of cerebral oxygen extraction fraction and cerebral metabolic rate of oxygen using TRUST measured venous oxygen saturation, peripheral pulse oximetry and global cerebral blood flow, Equations [3] [4] [5] [6] [7] , in healthy subjects and subjects with sickle cell disease (red diamonds) with respect to oxygen content using three separate T 2b models. Similar to 
DISCUSSION
This work uses validated empirical techniques and the blood of subjects with sickle cell disease to derive an HbS T 2b model that confers improved Y v predictions in SCD when to compared with existing T 2b models. These Y v predictions and the resulting physiological conclusions are contradictory to recently published MR oximetry results in SCD (9, 18, 19) . Given the documented limitations of the extrapolating the bovine T 2b models outside its calibrated range (13) , this work calls into question recent MR oximetry conclusions (9, 18, 19) and demonstrates that SCD patients exhibit decreased OEF proportional to their level of anemia.
To date, all existing MR oximetry Y v measurements in SCD subjects were derived using a bovine T 2b model (12) , which has several limitations for use in SCD (9, 18, 19) . First, the bovine T 2b model was originally defined over a hematocrit range from (35-55%) and extrapolates poorly to hematocrit ranges observed in anemic subjects (13) . Next, bovine red blood cells are smaller than human red blood cells and do not aggregate or form rouleux (20) . Shape of the exchange unit is a fundamental property in Luz Meiboom T 2b models (5) and red cell aggregation has been shown to decrease the relaxivity of blood (21) . These limitations were addressed by previous calibration experiments performed in whole human blood (HbA model) over a wide hematocrit range of 10-55% (13) . However, neither the bovine, nor the HbA model account for the pathologic, hematological, or rheological properties unique to whole, sickle cell blood.
Sickle Model for T 2b
When deoxygenated, HbS molecules undergo a double nucleation process, rapidly polymerizing into long rigid fibers within the red blood cell (22) (23) (24) . These polymer fibers often deform and may lyse the red blood cell membrane. Although the kinetics of hemoglobin polymerization and cellular deformation have been well described (22) (23) (24) , the implications of this phenomenon on magnetic transverse relaxation is unknown, prompting the ex vivo T 2b calibration study.
Blood transverse relaxation rate was linear with (1-Y) 2 , similar to other Luz-Meiboom based models (25, 26) . Unlike the HbA T 2b model, the HbS T 2b model was independent of hematocrit. This may be due, in part, to the relatively small HCT range studied in our patients with SCD. We might have been able to demonstrate a T 2b -hematocrit relationship by artificially manipulating the blood over a broader hematocrit range. However, sickle red blood cells are fragile, and we aimed to minimize red cell mechanical stressor and hemolysis. Alternatively, the relaxation rate of sickle blood may be intrinsically less hematocrit sensitive. According to the two compartment exchange relationship (5), the slope of (1-Y) 2 is governed by size, shape, and permeability of the cellular environment. In normal blood, shape and permeability are relatively constant across subjects and oxygenation status (13) . In SCD blood, red cell shape and permeability (27, 28) may vary dramatically across subjects and oxygenation status, potentially dwarfing the hematocrit dependency. A similar hematocrit independence was previously observed in deoxygenated SCD blood T 1 measurements (14) . This is striking because T 1 is even more hematocrit dependent than T 2 measurements (15) . Other factors, such as the presence of hemolysis (29) and iron inclusion bodies (30) , could also add variability into the empirical relationships.
Surprisingly, the concentration of HbS contributed little to the observed relaxivity (r 2 ¼ 0.04), suggesting that the red blood cell shape, surface area, and/or permeability abnormalities responsible for the transverse relaxivity changes are more enigmatic than a simple relationship with HbS concentration. The weak relationship between relaxation and HbS concentration suggests that the HbS T 2b model is valid across sickle cell phenotypes. This is clinically fortuitous for MR oximetry, in that HbS concentration can be difficult to know precisely without hemoglobin electrophoresis testing. Further evidence that sickle hemoglobin is acting through an indirect mechanism, such as shape change and permeability, is that the sickle cell trait subjects follow the HbA T 2b calibration even though they have 30-40% HbS concentration (Fig. 3) . In sickle cell trait, hemoglobin rarely polymerizes and the red blood cell are morphologically normal under most physiologic conditions because every cell contains a stable mixture of normal and sickle hemoglobin (23) . Despite the complexity of the sickle cell whole blood relaxation, our HbS T 2b model accounted for over 98% of the variability in the ex vivo measurements in the presence of broad range of HbS genotypes and HbS concentrations. Importantly, our calibration was also consistent with independent observations in six nontransfused homozygous sickle cell disease patients (31) .
In Vivo TRUST and Using the Sickle Model
In light of the newly derived HbS T 2b model, previous physiologic interpretations using the bovine T 2b model should be reexamined.
Predictions of the Bovine Model
In our data, the bovine model predicted a direct relationship between Y v increased and oxygen content whereas OEF and CMRO 2 varied inversely, replicating previous observations (9, 18, 19) . Those authors concluded that cerebral autoregulation was impaired in patients with SCD, similar to patient with chronic renal disease (32) and critical carotid stenosis (33) , resulting in elevated OEF (9) . However, no previous, non-MR cerebral oxygenation study in patients with SCD using PET or nitrous oxide methods has observed elevated cerebral OEF as a pathophysiologic consequence (34, 35) . To the contrary, studies have denoted elevated peripheral Y v in anemic subjects (36) , which is exacerbated during SCD pain crisis (37) . Furthermore, the SCD patients in our study were healthy, well managed since birth, had normal MRA and were free from known stoke. Therefore, given the proven biases demonstrated in the bovine model for hematocrit <35% (13) (Fig. 4) , we argue that the increased OEF and CMRO 2 in anemic subjects predicted by this model and reported previously may be spurious.
Predictions for the HbS Model
This work demonstrates several reasons why the presented HbS model is superior to existing T 2b calibration models when used in patients with sickle cell disease. First, the HbS model statistically outperformed both the bovine and HbA T 2b models. In vivo, intersubject variability in the SCD subjects, reflected by the coefficient of variability in Y v and OEF estimates, was lowest when the HbS was used. Second, while the predicted cerebral Y v and OEF using the HbS T 2b model seem paradoxical, they correlated well with peripheral oxygen extraction (Fig. 7) . Although the cerebral vasculature is under distinct autoregulatory control from the systemic vasculature, Figure 7 suggests that both the systemic and cerebral oxygen delivery are increased relative to demand. Furthermore, the loss of correlation between peripheral and cerebral Y v following multivariate analysis with oxygen content, further suggests anemia and/or high flow are driving reduced oxygen extraction in both vascular beds. It is important to note that the peripheral oximetry measurements are robust to hemoglobin subtypes, changes in hemoglobin dissociation, and corrected for dyshemoglobins (carboxyhemoglobin, methemoglobin). Third, there is a historical precedent for the observation of decreased oxygen extraction with anemia. Lower cerebral arterio-venous oxygen difference (35) and elevated systemic venous oxygenation have been described in SCD patients but the mechanism remains unclear (36) . Furthermore, a highly defensible explanation for decreased oxygen extraction in anemic patients is outlined below.
Microvascular Arteriovenous Shunting
In this work, we observed that at higher levels of anemia and cerebral blood flow, there is the lowest levels of oxygen extraction and usage (Fig. 6 ). This mismatch in local tissue oxygen delivery and bulk, organ oxygen delivery is likely caused by microvascular arteriovenous shunting. Recent work using a pseudo continuous arterial spin labeling has demonstrated that cerebral vascular shunting may be present in high cerebral blood flow populations with reduced microvascular transit time such as sickle cell disease, other anemic syndromes and pediatric populations (38, 39) . Shunting pathophysiology has also been observed in several other vascular beds in SCD (40, 41) , which is exacerbated during hyperemic flow conditions common in crisis (42) . Several analytical microvascular models have also shown that nonlinear matching between CBF and CMRO 2 leads to reduced OEF during hyperemia due to oxygen diffusion limitations at the microvascular level (43) (44) (45) ; however, this is an area of ongoing debate (46) .
Uncoupling between CBF and CMRO 2 is also a well described phenomenon following the acute hyperemia during the BOLD response (47) . Additionally, analytical and animal work has shown that variability in microvascular transit time leads to diminished OEF and apparent uncoupling of OEF and CMRO 2 (44, 48) . SCD subjects are known to have microvascular damage that leads to highly heterogeneous microvascular bed (49) and shortened transit times (50) , likely contributing to the observed decrease in global OEF.
At this time, it is unclear whether the decreased CMRO 2 is primary or secondary to the diminished local tissue oxygen usage. On one hand, decreased CMRO 2 may be a protective mechanism staving off more catastrophic ischemia, similar to hibernation. On the other hand, microvascular arteriovenous shunting may be reducing the bioavailability of oxygen, driving down CMRO 2 .
Either way, the microvascular arteriovenous shunting hypothesis is provocative and understanding the interplay of macro and microvascular oxygen transport may impact treatment strategies in SCD. For instance, increasing oxygen carrying capacity, through transfusions, hydroxyurea or other pharmacological means not only increases oxygen bioavailability but may also jointly slow blood flow thereby improving oxygen exchange. However, future therapies in SCD must balance oxygen transport kinetics with the impact of increased blood viscosity, capillary transit time heterogeneity, hemoglobin polymerization and red cell sickling. Further work is necessary to characterize the interplay between cerebral blood flow, capillary transit heterogeneity, and cerebral oxygenation in sickle cell disease subjects.
Limitations
The presented data should be considered within their limitations. The ex vivo calibration studies place greater mechanical stress on sickle red blood cells than is encountered in vivo. More importantly, the red cells remain deoxygenated for a longer period time. In vivo, the red blood cell releases oxygen, transits the remaining microvasculature, and arrives in the imaging plane in a matter of seconds. Based on polymerization kinetics, intracellular polymerization has a rapid onset and relatively few red cells will undergo a shape change by the time blood is imaged in vivo using TRUST (24) . On the other hand, ex vivo, deoxygenation, and TRUST imaging can take many minutes, potentially amplifying the shape and permeability changes. Therefore, it is possible that the in vivo HbS T 2b model has behavior intermediate to the ex vivo HbA and HbS models. However, both the HbA and HbS models predict quite different behavior than the bovine model and are better aligned with non-MRI based oximetry results in SCD (34, 35) .
This study would have benefited from direct jugular venous sampling for validation. However, the barriers to doing so are formidable and no previous cerebral MRI oximetry study has performed this validation. Given the preponderance of evidence to date, we conclude that the HbS T 2b model should be provisionally used for MR oximetry in SCD subjects.
CONCLUSIONS
In conclusion, a de novo, ex vivo HbS T 2b model of sickle cell blood differs dramatically from bovine and Diminished OEF in SCD using TRUST MRIHbA T 2b models, suggesting that morphologic and/or hematologic changes of sickle cell containing blood are critically important to T 2b MRI oximetry estimation. TRUST oximetry shows that cerebral oxygen extraction and metabolism is lower in SCD subjects, suggesting hyperemic condition give rise to uncoupling in tissue oxygen delivery and oxygen usage. Future studies are needed to confirm these conclusions and their implications on ischemic cerebrovascular disease.
